nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP1A1—Dacarbazine—melanoma	0.169	0.249	CbGbCtD
Dexmedetomidine—CYP2E1—Dacarbazine—melanoma	0.13	0.192	CbGbCtD
Dexmedetomidine—CYP1A2—Carmustine—melanoma	0.124	0.183	CbGbCtD
Dexmedetomidine—CYP1A2—Vemurafenib—melanoma	0.0983	0.145	CbGbCtD
Dexmedetomidine—CYP2D6—Vemurafenib—melanoma	0.081	0.119	CbGbCtD
Dexmedetomidine—CYP1A2—Dacarbazine—melanoma	0.0754	0.111	CbGbCtD
Dexmedetomidine—Acute respiratory distress syndrome—Docetaxel—melanoma	0.00364	0.0213	CcSEcCtD
Dexmedetomidine—Rigors—Vemurafenib—melanoma	0.00343	0.0201	CcSEcCtD
Dexmedetomidine—Gamma-glutamyltransferase increased—Vemurafenib—melanoma	0.0034	0.0199	CcSEcCtD
Dexmedetomidine—Disorder sight—Temozolomide—melanoma	0.003	0.0176	CcSEcCtD
Dexmedetomidine—Photopsia—Docetaxel—melanoma	0.00299	0.0175	CcSEcCtD
Dexmedetomidine—Hypomagnesaemia—Bleomycin—melanoma	0.00267	0.0156	CcSEcCtD
Dexmedetomidine—Sinus tachycardia—Docetaxel—melanoma	0.00236	0.0138	CcSEcCtD
Dexmedetomidine—Atrial fibrillation—Vemurafenib—melanoma	0.00214	0.0125	CcSEcCtD
Dexmedetomidine—Rigors—Temozolomide—melanoma	0.00175	0.0103	CcSEcCtD
Dexmedetomidine—Gamma-glutamyltransferase increased—Temozolomide—melanoma	0.00174	0.0102	CcSEcCtD
Dexmedetomidine—Hypocalcaemia—Dactinomycin—melanoma	0.00173	0.0101	CcSEcCtD
Dexmedetomidine—Speech disorder—Carmustine—melanoma	0.00172	0.0101	CcSEcCtD
Dexmedetomidine—Speech disorder—Temozolomide—melanoma	0.00166	0.00973	CcSEcCtD
Dexmedetomidine—Wheezing—Bleomycin—melanoma	0.00165	0.00964	CcSEcCtD
Dexmedetomidine—Leukocytosis—Carmustine—melanoma	0.00157	0.00922	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Temozolomide—melanoma	0.00157	0.0092	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Vemurafenib—melanoma	0.00153	0.00898	CcSEcCtD
Dexmedetomidine—Respiratory failure—Temozolomide—melanoma	0.00146	0.00852	CcSEcCtD
Dexmedetomidine—Supraventricular tachycardia—Docetaxel—melanoma	0.00145	0.0085	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Temozolomide—melanoma	0.00143	0.00837	CcSEcCtD
Dexmedetomidine—Pharyngolaryngeal pain—Docetaxel—melanoma	0.00141	0.00825	CcSEcCtD
Dexmedetomidine—Laryngeal pain—Docetaxel—melanoma	0.00139	0.00817	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Vemurafenib—melanoma	0.00138	0.0081	CcSEcCtD
Dexmedetomidine—Haemoglobin decreased—Docetaxel—melanoma	0.00138	0.00809	CcSEcCtD
Dexmedetomidine—Sepsis—Dactinomycin—melanoma	0.00137	0.00803	CcSEcCtD
Dexmedetomidine—Neuralgia—Docetaxel—melanoma	0.00137	0.00801	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Vemurafenib—melanoma	0.0013	0.00763	CcSEcCtD
Dexmedetomidine—Abnormal vision—Carmustine—melanoma	0.00129	0.00755	CcSEcCtD
Dexmedetomidine—Sepsis—Carmustine—melanoma	0.00128	0.00752	CcSEcCtD
Dexmedetomidine—Angiopathy—Vemurafenib—melanoma	0.00127	0.00746	CcSEcCtD
Dexmedetomidine—Neuritis—Docetaxel—melanoma	0.00127	0.00746	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Vemurafenib—melanoma	0.00127	0.00741	CcSEcCtD
Dexmedetomidine—Chills—Vemurafenib—melanoma	0.00126	0.00738	CcSEcCtD
Dexmedetomidine—Abnormal vision—Temozolomide—melanoma	0.00125	0.0073	CcSEcCtD
Dexmedetomidine—Pleural effusion—Docetaxel—melanoma	0.00124	0.00727	CcSEcCtD
Dexmedetomidine—Malnutrition—Vemurafenib—melanoma	0.00122	0.00716	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Temozolomide—melanoma	0.00119	0.00699	CcSEcCtD
Dexmedetomidine—Myocardial ischaemia—Docetaxel—melanoma	0.00118	0.00692	CcSEcCtD
Dexmedetomidine—Rigors—Docetaxel—melanoma	0.00116	0.00682	CcSEcCtD
Dexmedetomidine—Thirst—Temozolomide—melanoma	0.00109	0.00638	CcSEcCtD
Dexmedetomidine—Bronchospasm—Bleomycin—melanoma	0.00105	0.00612	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Docetaxel—melanoma	0.00105	0.00612	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.00103	0.00605	CcSEcCtD
Dexmedetomidine—Oliguria—Docetaxel—melanoma	0.00103	0.00604	CcSEcCtD
Dexmedetomidine—Infection—Vemurafenib—melanoma	0.000991	0.00581	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Carmustine—melanoma	0.000977	0.00572	CcSEcCtD
Dexmedetomidine—Respiratory failure—Docetaxel—melanoma	0.000968	0.00567	CcSEcCtD
Dexmedetomidine—Pneumonia—Bleomycin—melanoma	0.000953	0.00558	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Docetaxel—melanoma	0.00095	0.00557	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Temozolomide—melanoma	0.000944	0.00553	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Bleomycin—melanoma	0.000934	0.00547	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Temozolomide—melanoma	0.000934	0.00547	CcSEcCtD
Dexmedetomidine—Hypotension—Vemurafenib—melanoma	0.000932	0.00546	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Bleomycin—melanoma	0.000929	0.00544	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Temozolomide—melanoma	0.000915	0.00536	CcSEcCtD
Dexmedetomidine—Abdominal distension—Temozolomide—melanoma	0.000903	0.00529	CcSEcCtD
Dexmedetomidine—Fluid retention—Docetaxel—melanoma	0.000902	0.00528	CcSEcCtD
Dexmedetomidine—Pneumonia—Dactinomycin—melanoma	0.000889	0.00521	CcSEcCtD
Dexmedetomidine—Sweating increased—Temozolomide—melanoma	0.000873	0.00512	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Vemurafenib—melanoma	0.000861	0.00504	CcSEcCtD
Dexmedetomidine—Haemoglobin—Bleomycin—melanoma	0.000855	0.00501	CcSEcCtD
Dexmedetomidine—Constipation—Vemurafenib—melanoma	0.000853	0.005	CcSEcCtD
Dexmedetomidine—Haemorrhage—Bleomycin—melanoma	0.000851	0.00498	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Docetaxel—melanoma	0.000846	0.00495	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Carmustine—melanoma	0.000837	0.0049	CcSEcCtD
Dexmedetomidine—Pneumonia—Carmustine—melanoma	0.000832	0.00487	CcSEcCtD
Dexmedetomidine—Sepsis—Docetaxel—melanoma	0.000825	0.00483	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Carmustine—melanoma	0.000811	0.00475	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Temozolomide—melanoma	0.000809	0.00474	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Carmustine—melanoma	0.000804	0.00471	CcSEcCtD
Dexmedetomidine—Pneumonia—Temozolomide—melanoma	0.000804	0.00471	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Docetaxel—melanoma	0.000793	0.00465	CcSEcCtD
Dexmedetomidine—Body temperature increased—Vemurafenib—melanoma	0.000789	0.00462	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Temozolomide—melanoma	0.000784	0.00459	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Temozolomide—melanoma	0.000777	0.00455	CcSEcCtD
Dexmedetomidine—Chills—Bleomycin—melanoma	0.000763	0.00447	CcSEcCtD
Dexmedetomidine—Haemoglobin—Carmustine—melanoma	0.000746	0.00437	CcSEcCtD
Dexmedetomidine—Haemorrhage—Carmustine—melanoma	0.000743	0.00435	CcSEcCtD
Dexmedetomidine—Hallucination—Carmustine—melanoma	0.000739	0.00433	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Carmustine—melanoma	0.000732	0.00428	CcSEcCtD
Dexmedetomidine—Atrial fibrillation—Docetaxel—melanoma	0.000728	0.00426	CcSEcCtD
Dexmedetomidine—Haemoglobin—Temozolomide—melanoma	0.000721	0.00422	CcSEcCtD
Dexmedetomidine—Haemorrhage—Temozolomide—melanoma	0.000718	0.0042	CcSEcCtD
Dexmedetomidine—Visual impairment—Carmustine—melanoma	0.000716	0.00419	CcSEcCtD
Dexmedetomidine—Hallucination—Temozolomide—melanoma	0.000714	0.00418	CcSEcCtD
Dexmedetomidine—Chills—Dactinomycin—melanoma	0.000712	0.00417	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Temozolomide—melanoma	0.000707	0.00414	CcSEcCtD
Dexmedetomidine—Visual impairment—Temozolomide—melanoma	0.000692	0.00405	CcSEcCtD
Dexmedetomidine—Anaemia—Bleomycin—melanoma	0.000685	0.00401	CcSEcCtD
Dexmedetomidine—Diarrhoea—Vemurafenib—melanoma	0.000683	0.004	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Temozolomide—melanoma	0.000666	0.0039	CcSEcCtD
Dexmedetomidine—Arrhythmia—Carmustine—melanoma	0.000663	0.00389	CcSEcCtD
Dexmedetomidine—Dizziness—Vemurafenib—melanoma	0.00066	0.00386	CcSEcCtD
Dexmedetomidine—Angiopathy—Temozolomide—melanoma	0.000651	0.00381	CcSEcCtD
Dexmedetomidine—Mental disorder—Carmustine—melanoma	0.000651	0.00381	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Temozolomide—melanoma	0.000647	0.00379	CcSEcCtD
Dexmedetomidine—Malnutrition—Carmustine—melanoma	0.000647	0.00379	CcSEcCtD
Dexmedetomidine—Chills—Temozolomide—melanoma	0.000644	0.00377	CcSEcCtD
Dexmedetomidine—Anaemia—Dactinomycin—melanoma	0.000638	0.00374	CcSEcCtD
Dexmedetomidine—Vomiting—Vemurafenib—melanoma	0.000634	0.00372	CcSEcCtD
Dexmedetomidine—Rash—Vemurafenib—melanoma	0.000629	0.00368	CcSEcCtD
Dexmedetomidine—Mental disorder—Temozolomide—melanoma	0.000629	0.00368	CcSEcCtD
Dexmedetomidine—Dermatitis—Vemurafenib—melanoma	0.000628	0.00368	CcSEcCtD
Dexmedetomidine—Headache—Vemurafenib—melanoma	0.000625	0.00366	CcSEcCtD
Dexmedetomidine—Malnutrition—Temozolomide—melanoma	0.000625	0.00366	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000621	0.00364	CcSEcCtD
Dexmedetomidine—Confusional state—Bleomycin—melanoma	0.000609	0.00357	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Docetaxel—melanoma	0.000608	0.00356	CcSEcCtD
Dexmedetomidine—Infection—Bleomycin—melanoma	0.000601	0.00352	CcSEcCtD
Dexmedetomidine—Anaemia—Carmustine—melanoma	0.000598	0.0035	CcSEcCtD
Dexmedetomidine—Agitation—Carmustine—melanoma	0.000594	0.00348	CcSEcCtD
Dexmedetomidine—Nausea—Vemurafenib—melanoma	0.000593	0.00347	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Bleomycin—melanoma	0.000592	0.00347	CcSEcCtD
Dexmedetomidine—Bronchospasm—Docetaxel—melanoma	0.000587	0.00344	CcSEcCtD
Dexmedetomidine—Anaemia—Temozolomide—melanoma	0.000577	0.00338	CcSEcCtD
Dexmedetomidine—Agitation—Temozolomide—melanoma	0.000574	0.00336	CcSEcCtD
Dexmedetomidine—Hypotension—Bleomycin—melanoma	0.000565	0.00331	CcSEcCtD
Dexmedetomidine—Convulsion—Carmustine—melanoma	0.00056	0.00328	CcSEcCtD
Dexmedetomidine—Infection—Dactinomycin—melanoma	0.00056	0.00328	CcSEcCtD
Dexmedetomidine—Hypertension—Carmustine—melanoma	0.000558	0.00327	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Dactinomycin—melanoma	0.000552	0.00323	CcSEcCtD
Dexmedetomidine—Anxiety—Carmustine—melanoma	0.000549	0.00321	CcSEcCtD
Dexmedetomidine—Convulsion—Temozolomide—melanoma	0.000541	0.00317	CcSEcCtD
Dexmedetomidine—Hypertension—Temozolomide—melanoma	0.000539	0.00316	CcSEcCtD
Dexmedetomidine—Dyspnoea—Bleomycin—melanoma	0.000539	0.00316	CcSEcCtD
Dexmedetomidine—Pneumonia—Docetaxel—melanoma	0.000535	0.00313	CcSEcCtD
Dexmedetomidine—Confusional state—Carmustine—melanoma	0.000532	0.00312	CcSEcCtD
Dexmedetomidine—Anxiety—Temozolomide—melanoma	0.00053	0.0031	CcSEcCtD
Dexmedetomidine—Infection—Carmustine—melanoma	0.000524	0.00307	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Docetaxel—melanoma	0.000524	0.00307	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Docetaxel—melanoma	0.000521	0.00305	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Docetaxel—melanoma	0.000521	0.00305	CcSEcCtD
Dexmedetomidine—Dry mouth—Temozolomide—melanoma	0.00052	0.00305	CcSEcCtD
Dexmedetomidine—Pain—Bleomycin—melanoma	0.000517	0.00303	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Carmustine—melanoma	0.000517	0.00303	CcSEcCtD
Dexmedetomidine—Tachycardia—Carmustine—melanoma	0.000515	0.00302	CcSEcCtD
Dexmedetomidine—Confusional state—Temozolomide—melanoma	0.000514	0.00301	CcSEcCtD
Dexmedetomidine—Infection—Temozolomide—melanoma	0.000507	0.00297	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Temozolomide—melanoma	0.000499	0.00292	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Bleomycin—melanoma	0.000498	0.00292	CcSEcCtD
Dexmedetomidine—Hypotension—Carmustine—melanoma	0.000493	0.00289	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Temozolomide—melanoma	0.000493	0.00289	CcSEcCtD
Dexmedetomidine—Pain—Dactinomycin—melanoma	0.000482	0.00282	CcSEcCtD
Dexmedetomidine—Haemoglobin—Docetaxel—melanoma	0.00048	0.00281	CcSEcCtD
Dexmedetomidine—Body temperature increased—Bleomycin—melanoma	0.000478	0.0028	CcSEcCtD
Dexmedetomidine—Haemorrhage—Docetaxel—melanoma	0.000477	0.0028	CcSEcCtD
Dexmedetomidine—Dyspnoea—Carmustine—melanoma	0.00047	0.00276	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Docetaxel—melanoma	0.00047	0.00275	CcSEcCtD
Dexmedetomidine—Somnolence—Carmustine—melanoma	0.000469	0.00275	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Dactinomycin—melanoma	0.000465	0.00272	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Dactinomycin—melanoma	0.000461	0.0027	CcSEcCtD
Dexmedetomidine—Visual impairment—Docetaxel—melanoma	0.00046	0.00269	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Carmustine—melanoma	0.000456	0.00267	CcSEcCtD
Dexmedetomidine—Dyspnoea—Temozolomide—melanoma	0.000455	0.00266	CcSEcCtD
Dexmedetomidine—Somnolence—Temozolomide—melanoma	0.000453	0.00265	CcSEcCtD
Dexmedetomidine—Constipation—Carmustine—melanoma	0.000451	0.00264	CcSEcCtD
Dexmedetomidine—Pain—Carmustine—melanoma	0.000451	0.00264	CcSEcCtD
Dexmedetomidine—Abdominal pain—Dactinomycin—melanoma	0.000446	0.00261	CcSEcCtD
Dexmedetomidine—Body temperature increased—Dactinomycin—melanoma	0.000446	0.00261	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Docetaxel—melanoma	0.000443	0.00259	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Temozolomide—melanoma	0.00044	0.00258	CcSEcCtD
Dexmedetomidine—Pain—Temozolomide—melanoma	0.000436	0.00255	CcSEcCtD
Dexmedetomidine—Constipation—Temozolomide—melanoma	0.000436	0.00255	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Carmustine—melanoma	0.000435	0.00255	CcSEcCtD
Dexmedetomidine—Angiopathy—Docetaxel—melanoma	0.000433	0.00254	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Carmustine—melanoma	0.000431	0.00253	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Docetaxel—melanoma	0.00043	0.00252	CcSEcCtD
Dexmedetomidine—Chills—Docetaxel—melanoma	0.000428	0.00251	CcSEcCtD
Dexmedetomidine—Arrhythmia—Docetaxel—melanoma	0.000426	0.0025	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Temozolomide—melanoma	0.00042	0.00246	CcSEcCtD
Dexmedetomidine—Mental disorder—Docetaxel—melanoma	0.000418	0.00245	CcSEcCtD
Dexmedetomidine—Body temperature increased—Carmustine—melanoma	0.000417	0.00244	CcSEcCtD
Dexmedetomidine—Abdominal pain—Carmustine—melanoma	0.000417	0.00244	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Temozolomide—melanoma	0.000417	0.00244	CcSEcCtD
Dexmedetomidine—Malnutrition—Docetaxel—melanoma	0.000415	0.00243	CcSEcCtD
Dexmedetomidine—Body temperature increased—Temozolomide—melanoma	0.000403	0.00236	CcSEcCtD
Dexmedetomidine—Abdominal pain—Temozolomide—melanoma	0.000403	0.00236	CcSEcCtD
Dexmedetomidine—Diarrhoea—Dactinomycin—melanoma	0.000386	0.00226	CcSEcCtD
Dexmedetomidine—Vomiting—Bleomycin—melanoma	0.000384	0.00225	CcSEcCtD
Dexmedetomidine—Anaemia—Docetaxel—melanoma	0.000384	0.00225	CcSEcCtD
Dexmedetomidine—Rash—Bleomycin—melanoma	0.000381	0.00223	CcSEcCtD
Dexmedetomidine—Dermatitis—Bleomycin—melanoma	0.000381	0.00223	CcSEcCtD
Dexmedetomidine—Diarrhoea—Carmustine—melanoma	0.000361	0.00211	CcSEcCtD
Dexmedetomidine—Convulsion—Docetaxel—melanoma	0.00036	0.00211	CcSEcCtD
Dexmedetomidine—Nausea—Bleomycin—melanoma	0.000359	0.0021	CcSEcCtD
Dexmedetomidine—Hypertension—Docetaxel—melanoma	0.000359	0.0021	CcSEcCtD
Dexmedetomidine—Vomiting—Dactinomycin—melanoma	0.000358	0.0021	CcSEcCtD
Dexmedetomidine—Rash—Dactinomycin—melanoma	0.000355	0.00208	CcSEcCtD
Dexmedetomidine—Dizziness—Carmustine—melanoma	0.000349	0.00204	CcSEcCtD
Dexmedetomidine—Diarrhoea—Temozolomide—melanoma	0.000349	0.00204	CcSEcCtD
Dexmedetomidine—Dry mouth—Docetaxel—melanoma	0.000346	0.00203	CcSEcCtD
Dexmedetomidine—Confusional state—Docetaxel—melanoma	0.000342	0.002	CcSEcCtD
Dexmedetomidine—Dizziness—Temozolomide—melanoma	0.000337	0.00197	CcSEcCtD
Dexmedetomidine—Infection—Docetaxel—melanoma	0.000337	0.00197	CcSEcCtD
Dexmedetomidine—Vomiting—Carmustine—melanoma	0.000335	0.00196	CcSEcCtD
Dexmedetomidine—Nausea—Dactinomycin—melanoma	0.000335	0.00196	CcSEcCtD
Dexmedetomidine—Rash—Carmustine—melanoma	0.000333	0.00195	CcSEcCtD
Dexmedetomidine—Dermatitis—Carmustine—melanoma	0.000332	0.00195	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Docetaxel—melanoma	0.000332	0.00194	CcSEcCtD
Dexmedetomidine—Tachycardia—Docetaxel—melanoma	0.000331	0.00194	CcSEcCtD
Dexmedetomidine—Headache—Carmustine—melanoma	0.000331	0.00194	CcSEcCtD
Dexmedetomidine—Vomiting—Temozolomide—melanoma	0.000324	0.0019	CcSEcCtD
Dexmedetomidine—Rash—Temozolomide—melanoma	0.000321	0.00188	CcSEcCtD
Dexmedetomidine—Dermatitis—Temozolomide—melanoma	0.000321	0.00188	CcSEcCtD
Dexmedetomidine—Headache—Temozolomide—melanoma	0.000319	0.00187	CcSEcCtD
Dexmedetomidine—Hypotension—Docetaxel—melanoma	0.000317	0.00186	CcSEcCtD
Dexmedetomidine—Nausea—Carmustine—melanoma	0.000313	0.00184	CcSEcCtD
Dexmedetomidine—Nausea—Temozolomide—melanoma	0.000303	0.00177	CcSEcCtD
Dexmedetomidine—Dyspnoea—Docetaxel—melanoma	0.000302	0.00177	CcSEcCtD
Dexmedetomidine—Somnolence—Docetaxel—melanoma	0.000301	0.00177	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Docetaxel—melanoma	0.000293	0.00171	CcSEcCtD
Dexmedetomidine—Pain—Docetaxel—melanoma	0.00029	0.0017	CcSEcCtD
Dexmedetomidine—Constipation—Docetaxel—melanoma	0.00029	0.0017	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Docetaxel—melanoma	0.000279	0.00164	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Docetaxel—melanoma	0.000277	0.00162	CcSEcCtD
Dexmedetomidine—Abdominal pain—Docetaxel—melanoma	0.000268	0.00157	CcSEcCtD
Dexmedetomidine—Body temperature increased—Docetaxel—melanoma	0.000268	0.00157	CcSEcCtD
Dexmedetomidine—Diarrhoea—Docetaxel—melanoma	0.000232	0.00136	CcSEcCtD
Dexmedetomidine—Dizziness—Docetaxel—melanoma	0.000224	0.00131	CcSEcCtD
Dexmedetomidine—Vomiting—Docetaxel—melanoma	0.000216	0.00126	CcSEcCtD
Dexmedetomidine—Rash—Docetaxel—melanoma	0.000214	0.00125	CcSEcCtD
Dexmedetomidine—Dermatitis—Docetaxel—melanoma	0.000214	0.00125	CcSEcCtD
Dexmedetomidine—Headache—Docetaxel—melanoma	0.000212	0.00124	CcSEcCtD
Dexmedetomidine—Nausea—Docetaxel—melanoma	0.000201	0.00118	CcSEcCtD
Dexmedetomidine—ADRA2B—Signaling by GPCR—KRAS—melanoma	1.1e-05	7.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ERBB2—melanoma	1.1e-05	7.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CB—melanoma	1.1e-05	7.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IGF1—melanoma	1.1e-05	7.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—AKT1—melanoma	1.1e-05	7.26e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.1e-05	7.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—MAPK1—melanoma	1.09e-05	7.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EGFR—melanoma	1.09e-05	7.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CB—melanoma	1.09e-05	7.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTGS2—melanoma	1.09e-05	7.21e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP1B1—melanoma	1.08e-05	7.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IGF1—melanoma	1.08e-05	7.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—FGF2—melanoma	1.08e-05	7.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—MAPK1—melanoma	1.07e-05	7.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EGFR—melanoma	1.07e-05	7.12e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CG—melanoma	1.07e-05	7.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAP2K1—melanoma	1.06e-05	7.02e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.06e-05	7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KDR—melanoma	1.06e-05	7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CD—melanoma	1.05e-05	6.98e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ABCB1—melanoma	1.05e-05	6.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCL8—melanoma	1.05e-05	6.93e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAP2K1—melanoma	1.04e-05	6.91e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CA—melanoma	1.04e-05	6.91e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—HRAS—melanoma	1.04e-05	6.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CD—melanoma	1.04e-05	6.87e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PPARG—melanoma	1.03e-05	6.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—KRAS—melanoma	1.03e-05	6.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CA—melanoma	1.03e-05	6.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CD—melanoma	1.02e-05	6.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1B—melanoma	1.02e-05	6.77e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FN1—melanoma	1.02e-05	6.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—KRAS—melanoma	1.02e-05	6.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—melanoma	1.01e-05	6.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKT1—melanoma	1.01e-05	6.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MDM2—melanoma	1.01e-05	6.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ALB—melanoma	1.01e-05	6.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FGF2—melanoma	1.01e-05	6.68e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CG—melanoma	1.01e-05	6.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CASP3—melanoma	1e-05	6.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—melanoma	1e-05	6.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ERBB2—melanoma	9.96e-06	6.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOTCH1—melanoma	9.95e-06	6.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL6—melanoma	9.95e-06	6.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FGF2—melanoma	9.93e-06	6.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CB—melanoma	9.83e-06	6.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CD80—melanoma	9.75e-06	6.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—melanoma	9.75e-06	6.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KIT—melanoma	9.73e-06	6.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APC—melanoma	9.73e-06	6.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CG—melanoma	9.73e-06	6.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—NRAS—melanoma	9.73e-06	6.45e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PPARG—melanoma	9.73e-06	6.44e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PRKCA—melanoma	9.68e-06	6.41e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CTNNB1—melanoma	9.65e-06	6.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGF—melanoma	9.62e-06	6.37e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ERCC2—melanoma	9.6e-06	6.36e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	9.55e-06	6.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTEN—melanoma	9.49e-06	6.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—melanoma	9.48e-06	6.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MMP9—melanoma	9.46e-06	6.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL8—melanoma	9.45e-06	6.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MDM2—melanoma	9.44e-06	6.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1A—melanoma	9.43e-06	6.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTEN—melanoma	9.41e-06	6.23e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CD—melanoma	9.4e-06	6.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HRAS—melanoma	9.38e-06	6.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NFKB1—melanoma	9.36e-06	6.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—melanoma	9.33e-06	6.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—MAPK3—melanoma	9.32e-06	6.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ERBB2—melanoma	9.3e-06	6.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MDM2—melanoma	9.29e-06	6.15e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ALB—melanoma	9.28e-06	6.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1B—melanoma	9.22e-06	6.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CB—melanoma	9.18e-06	6.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKT1—melanoma	9.18e-06	6.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ERBB2—melanoma	9.16e-06	6.06e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BRAF—melanoma	9.15e-06	6.06e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKT1—melanoma	9.13e-06	6.04e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CASP3—melanoma	9.04e-06	5.99e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CB—melanoma	9.04e-06	5.98e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—melanoma	9.03e-06	5.98e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL6—melanoma	8.98e-06	5.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CB—melanoma	8.92e-06	5.91e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ABCB1—melanoma	8.91e-06	5.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF1—melanoma	8.91e-06	5.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—MAPK1—melanoma	8.87e-06	5.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—melanoma	8.87e-06	5.87e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CD—melanoma	8.86e-06	5.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—melanoma	8.84e-06	5.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL8—melanoma	8.82e-06	5.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—melanoma	8.8e-06	5.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HRAS—melanoma	8.77e-06	5.81e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ALB—melanoma	8.75e-06	5.79e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CTNNB1—melanoma	8.71e-06	5.77e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL8—melanoma	8.68e-06	5.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HRAS—melanoma	8.63e-06	5.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1B—melanoma	8.62e-06	5.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAP2K1—melanoma	8.61e-06	5.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CD—melanoma	8.56e-06	5.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MMP9—melanoma	8.54e-06	5.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKT1—melanoma	8.52e-06	5.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1A—melanoma	8.51e-06	5.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—melanoma	8.5e-06	5.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTEN—melanoma	8.49e-06	5.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1B—melanoma	8.48e-06	5.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	8.48e-06	5.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NFKB1—melanoma	8.45e-06	5.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CASP3—melanoma	8.45e-06	5.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—melanoma	8.43e-06	5.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—melanoma	8.41e-06	5.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NRAS—melanoma	8.39e-06	5.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL6—melanoma	8.39e-06	5.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKT1—melanoma	8.39e-06	5.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—KRAS—melanoma	8.38e-06	5.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CASP3—melanoma	8.31e-06	5.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—melanoma	8.3e-06	5.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKT1—melanoma	8.29e-06	5.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL6—melanoma	8.26e-06	5.47e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—melanoma	8.22e-06	5.44e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PRKCA—melanoma	8.2e-06	5.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FGF2—melanoma	8.19e-06	5.43e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CB—melanoma	8.19e-06	5.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CTNNB1—melanoma	8.14e-06	5.39e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ERCC2—melanoma	8.14e-06	5.39e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—melanoma	8.12e-06	5.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—melanoma	8.09e-06	5.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK3—melanoma	8.04e-06	5.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CTNNB1—melanoma	8.01e-06	5.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MMP9—melanoma	7.98e-06	5.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1A—melanoma	7.95e-06	5.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTEN—melanoma	7.93e-06	5.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NFKB1—melanoma	7.9e-06	5.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MMP9—melanoma	7.85e-06	5.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1A—melanoma	7.83e-06	5.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—melanoma	7.82e-06	5.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTEN—melanoma	7.81e-06	5.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NFKB1—melanoma	7.77e-06	5.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKT1—melanoma	7.74e-06	5.13e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CB—melanoma	7.72e-06	5.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTEN—melanoma	7.71e-06	5.1e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	7.7e-06	5.1e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—melanoma	7.67e-06	5.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MDM2—melanoma	7.67e-06	5.08e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—melanoma	7.65e-06	5.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK1—melanoma	7.65e-06	5.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—melanoma	7.65e-06	5.06e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKT1—melanoma	7.62e-06	5.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—melanoma	7.6e-06	5.03e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CG—melanoma	7.59e-06	5.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NRAS—melanoma	7.58e-06	5.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ERBB2—melanoma	7.56e-06	5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CB—melanoma	7.46e-06	4.94e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PPARG—melanoma	7.32e-06	4.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK3—melanoma	7.26e-06	4.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KRAS—melanoma	7.22e-06	4.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL8—melanoma	7.17e-06	4.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—melanoma	7.17e-06	4.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HRAS—melanoma	7.12e-06	4.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—melanoma	7.1e-06	4.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NRAS—melanoma	7.08e-06	4.69e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTEN—melanoma	7.08e-06	4.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—melanoma	7.06e-06	4.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—melanoma	7.05e-06	4.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1B—melanoma	7e-06	4.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—melanoma	6.98e-06	4.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NRAS—melanoma	6.97e-06	4.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKT1—melanoma	6.92e-06	4.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK1—melanoma	6.91e-06	4.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—melanoma	6.9e-06	4.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CASP3—melanoma	6.86e-06	4.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—melanoma	6.85e-06	4.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL6—melanoma	6.82e-06	4.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK3—melanoma	6.78e-06	4.49e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	6.74e-06	4.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—melanoma	6.69e-06	4.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—melanoma	6.68e-06	4.42e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTEN—melanoma	6.67e-06	4.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK3—melanoma	6.67e-06	4.42e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CD—melanoma	6.67e-06	4.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—melanoma	6.64e-06	4.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CTNNB1—melanoma	6.61e-06	4.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—melanoma	6.59e-06	4.37e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ALB—melanoma	6.58e-06	4.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KRAS—melanoma	6.52e-06	4.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—melanoma	6.49e-06	4.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP9—melanoma	6.48e-06	4.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1A—melanoma	6.46e-06	4.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK1—melanoma	6.45e-06	4.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—melanoma	6.45e-06	4.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTEN—melanoma	6.44e-06	4.27e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CG—melanoma	6.43e-06	4.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—melanoma	6.42e-06	4.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NFKB1—melanoma	6.41e-06	4.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK1—melanoma	6.35e-06	4.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—melanoma	6.35e-06	4.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKT1—melanoma	6.29e-06	4.16e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PPARG—melanoma	6.2e-06	4.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HRAS—melanoma	6.14e-06	4.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KRAS—melanoma	6.09e-06	4.03e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KRAS—melanoma	6e-06	3.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—melanoma	5.99e-06	3.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL6—melanoma	5.88e-06	3.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—melanoma	5.82e-06	3.85e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CB—melanoma	5.81e-06	3.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—melanoma	5.8e-06	3.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—melanoma	5.76e-06	3.82e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—melanoma	5.76e-06	3.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NRAS—melanoma	5.75e-06	3.81e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CD—melanoma	5.65e-06	3.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—melanoma	5.6e-06	3.71e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ALB—melanoma	5.58e-06	3.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HRAS—melanoma	5.54e-06	3.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—melanoma	5.51e-06	3.65e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK3—melanoma	5.51e-06	3.65e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AKT1—melanoma	5.47e-06	3.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—melanoma	5.44e-06	3.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT1—melanoma	5.42e-06	3.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—melanoma	5.41e-06	3.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—melanoma	5.36e-06	3.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—melanoma	5.33e-06	3.53e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL6—melanoma	5.31e-06	3.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK1—melanoma	5.24e-06	3.47e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—melanoma	5.24e-06	3.47e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HRAS—melanoma	5.18e-06	3.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HRAS—melanoma	5.1e-06	3.38e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTEN—melanoma	5.02e-06	3.33e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—melanoma	4.99e-06	3.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6—melanoma	4.96e-06	3.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KRAS—melanoma	4.95e-06	3.28e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CB—melanoma	4.92e-06	3.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT1—melanoma	4.9e-06	3.24e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—melanoma	4.88e-06	3.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6—melanoma	4.88e-06	3.23e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—melanoma	4.71e-06	3.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT1—melanoma	4.57e-06	3.03e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—melanoma	4.55e-06	3.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT1—melanoma	4.5e-06	2.98e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AKT1—melanoma	4.44e-06	2.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—melanoma	4.4e-06	2.91e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTEN—melanoma	4.25e-06	2.82e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HRAS—melanoma	4.21e-06	2.79e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKT1—melanoma	4.08e-06	2.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6—melanoma	4.03e-06	2.67e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKT1—melanoma	3.85e-06	2.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT1—melanoma	3.71e-06	2.46e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—melanoma	3.54e-06	2.35e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—melanoma	3e-06	1.99e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKT1—melanoma	2.89e-06	1.92e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKT1—melanoma	2.45e-06	1.62e-05	CbGpPWpGaD
